Skip to Content
Author: The BCW

Leave a Comment

Regeneron COVID-19 Cocktail Used to Treat President  

http://thebcw.org/wp-content/uploads/2020/10/regeneron-1200×600-1.jpg

President Donald Trump praised BCW Member Regeneron for its REGN-COV2 treatment, a combination of two monoclonal antibodies, which is still in clinical trials. The treatment is designed to prevent the infectivity of SARS-CoV-2, the virus that causes COVID-19.

President Trump received the treatment last week, according to his physicians. The Tarrytown pharmaceutical company Wednesday said it submitted an application to the Food and Drug Administration for emergency approval to develop a limited 50,000 doses of the experimental antibody cocktail.

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. REGN-COV2 is currently being studied in two, Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals.

 

Two weeks ago the company announced that the result from Phase 1/2/3 trial were promising.

“After months of incredibly hard work by our talented team, we are extremely gratified to see that Regeneron’s antibody cocktail REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response. These patients were less likely to clear the virus on their own, and were at greater risk for prolonged symptoms. We are highly encouraged by the robust and consistent nature of these initial data, as well as the emerging well-tolerated safety profile, and we have begun discussing our findings with regulatory authorities while continuing our ongoing trials. In addition to having positive implications for REGN-COV2 trials and those of other antibody therapies, these data also support the promise of vaccines targeting the SARS-CoV-2 spike protein.”

 
Founded by physician-scientists more than 30 years ago, Regeneron’s science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

Similar News Items

The Business Council of Westchester released its 2024 Legislative Agenda and called on state lawmakers to embrace policies that support a sustainable economy and job creation. The BCW produces the Annual Legislative Agenda each year for federal, state and local representatives on behalf of the business community. Among the recommendations in its 44-page report, the […]

Read Article

The Business Council of Westchester is among 43 business organizations representing tens of thousands of businesses of all sectors and sizes across New York urging the Senate and Assembly to allocate funding in the Fiscal Year 2025 budget to address the unemployment insurance debt; as well as support the Governor’s proposals to sunset the state’s […]

Read Article

Congratulations to the Burn Center at Westchester Medical Center on being verified by the American Burn Association (ABA) as an Adult and Pediatric Burn Center. The verification was made after a rigorous and thorough review of Westchester Medical Center’s burn care program. With this verification, BCW Member Westchester Medical Center is now home to the […]

Read Article

Become A Member

Join the county’s largest and most influential business organization today.

JOIN NOW!
The Business Council of Westchester is committed to helping businesses market, learn, advocate, and grow. Over 80 events and programs are offered every year, giving our members ample opportunity to connect and meet with businesses representatives in the Westchester community and beyond.
Back to top